ReviewDiscover nano2026
Nanoparticle based drug delivery systems improve antimalarial efficacy and vaccine performance in African research and clinical settings.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria is a significant public health problem in sub-Saharan Africa, responsible for a large proportion of the world's malaria cases and deaths. Antimalarial drug resistance and the low efficacy of existing drugs, due to poor solubility, bioavailability, short half-life and non-specific distribution, highlight the importance of the development of better delivery strategies. The current systematic review focuses on the platforms that were developed or evaluated in Africa (2015-2025) involving nanoparticles.
methodsPubMed, Web of Science, and Scopus were searched for original experimental (in vitro, in vivo, clinical trials) studies on nanoparticle-mediated antimalarial drug delivery, vaccines, or immune modulation with explicit relevance to African research or populations. After screening 52 records and full-text assessment, 16 studies were included.
resultsSixteen studies described 14 distinct nanoparticle systems: lipid-based (38%), polymeric (19%), inorganic/metallic (25%), and protein/virus-like particles (19%). Lipid and polymeric nanoparticles achieved 80-95% parasitaemia reduction at reduced doses through enhanced solubility and sustained release. Inorganic carriers offered high loading and pH-triggered delivery, whereas R21/Matrix-M virus-like particles demonstrated 75-80% vaccine efficacy in large African Phase 2b/3 trials.
conclusionNanoparticle drug delivery demonstrates potentials in improving antimalarial efficacy, targeting, and safety, yet translation remains limited by manufacturing scale-up, regulatory gaps, and a lack of long-term toxicity data. Strengthening local production and South-South/North-South collaborations is essential to integrating these technologies into Africa's malaria control programmes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.